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Abstract. Glioma is one of the most common malignant
tumor types of the central nervous system. It is necessary to
identify biomarkers and novel therapeutic targets for glioma.
The purpose of the present study was to distinguish lipid
biomarkers with differential expression patterns in glioma
tissues and normal brain tissues by matrix assisted laser
desorption/ionization (MALDI)‑imaging and MALDI‑time of
flight (TOF)‑mass spectrometry (MS). Additionally, identification of lipid biomarkers was performed to describe novel
therapeutic targets for glioma treatment. A total of six tissues
from three patients with glioma and three control patients with
traumatic brain injury were analyzed using UltrafleXtreme
MALDI‑TOF/TOF. The expression levels of 15 lipid peaks
were higher in the TBT samples compared with in the GBT
samples. The expression levels of another 16 lipid peaks were
higher in the GBT samples compared with in the TBT samples.
14 peaks were identified as sphingomyelins using MS/MS.
Additional results were also obtained from experiments using
the glioma cell line U373‑MG. These results indicated that
treatment with the drug desipramine (Desi) inhibited the
accumulation of ceramide on the cell membranes of glioma
U373‑MG cells. Treatment with Desi inhibited the activation
of insulin‑like growth factor‑1 receptor and inhibited the
activation of proteins in the PI3K/Akt signaling pathway.
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Introduction
Glioma is the most common type of malignant brain tumor
in adults worldwide (1,2). The principal diagnosis methods
for patients with glioma include disease history questionnaires, nervous system physical examination and imaging
examination with different modalities (3). Since early glioma
prediction and diagnosis is difficult, the majority of patients are
diagnosed at a late stage. Typically, treatment for patients with
glioma involves maximal safe surgical resection, followed by
chemotherapy and radiotherapy. The prognosis of patients with
glioma is frequently poor due to its aggressive properties (4,5).
Hence, there is an urgent need to identify novel biomarkers
for glioma diagnosis and novel therapeutic targets to improve
patient survival.
Protein and lipid are two types of diagnostic biomarkers
for glioma (6‑8). Biomarkers may be identified from
patient samples, including serum, cerebrospinal fluid (CSF)
and glioma cells (9). Capillary morphogenesis protein 2
(CMG2) has been identified as a prognostic biomarker for
glioma, and CMG2 increased expression is associated with
increased tumor grade and poor patient survival (10). The
effect of protein biomarker T‑LAK cell‑originating protein
kinase (TOPK) expression on the outcome in malignant
glioma has been previously reported, revealing that low
TOPK expression is an independent predictor of longer
overall survival (11). Ribom et al (12) performed a comparative proteomics analysis with CSF samples from glioma
cases and revealed that α‑2‑Heremans‑Schmid glycoprotein
was highly expressed in the CSF of patients with low‑grade
disease. Iwadate et al (13) conducted survival prediction research in glioma based on proteomic analysis and
identified 37 protein biomarkers.
In addition to protein biomarkers, lipid biomarkers are also
required for the diagnosis and treatment of glioma. The matrix
assisted laser desorption/ionization (MALDI)‑imaging technique has been widely used in lipid biomarker research (14‑16).
Wildburger et al (15) identified lipids directly from glioblastoma tissues by MALDI‑imaging mass spectrometry (MS),
and a number of species of signaling lipids were observed.
Shrivas et al (17) identified phospholipids in mouse liver and
cerebellum tissue sections using an ionic matrix for enhanced
MALDI‑imaging MS.
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In the present study, three glioma brain tissue (GBT)
samples and three trauma brain tissue (TBT) samples were
collected to identify lipid biomarkers using MALDI‑time of
flight (TOF)‑tandem mass spectrometry (MS/MS). The lipid
biomarkers with differential expression were selected and
identified. The expression of a number of lipid biomarkers
with potential clinical significance was verified using the
MALDI‑imaging technique. In order to reveal the regulatory
mechanisms of lipid biomarkers in glioma signaling pathways,
the glioma cell line U373‑MG was cultured, and additional
research was performed regarding the PI3K/AKT signaling
pathway.
Materials and methods
Brain tissue samples. In the present study, three GBT samples
from patients with glioma (two women aged 46 and 55 years and
one man aged 60 years) and three TBT samples from patients
with traumatic brain injury (two men aged 48 and 50 years and
one woman aged 56 years) were collected following neurosurgery at The First Affiliated Hospital of Zhejiang University
School of Medicine (Hangzhou, China) in December 2013.
Informed consent was obtained from participants for the use
of their tissues in the present study. All diagnoses of glioma
were histopathologically confirmed.
Glioma cell culture. The human glioma cell line U373‑MG
was purchased from American Type Culture Collection
(ATCC). The U373‑MG ATCC cell line is a U‑251 derivative
according to Cellosaurus (https://web.expasy.org/cellosaurus/
CVCL_2219). It was directly used in the present study without
additional authentication. The cell line was cultured in DMEM
(Thermo Fisher Scientific, Inc.), supplemented with 1% penicillin/streptomycin and 10% FBS (Thermo Fisher Scientific,
Inc.). The cells were grown at 37˚C with 5% CO2 in a humidified incubator.
Biomarker identification with MALDI‑TOF‑MS/MS. GBTs
and TBTs were removed from the ‑80˚C freezer and cut into
10‑µm‑thick sections with a Leica CM950 freezing microtome
(Leica Microsystems GmbH) at ‑20˚C. Each tissue section was
pasted on the imaging slide and dried in a vacuum dryer for
45 min at room temperature. The imaging slide was placed into
the ImagePrep machine and flushed uniformly with matrix.
The imaging slide was placed on the MTP Slide Adapter II
and analyzed with MALDI‑TOF‑MS/MS. The mass scan range
was set at m/z: 0‑3,000. The mass spectrum data were analyzed
using FlexImaging software version 3.0 (Bruker Daltonics).
The lipid peaks were identified using MS/MS and results were
searched in the Human Metabolome Database (18).
Live staining. U373‑MG cells were cultured as aforementioned
in small glass dishes overnight so that they reach 60‑75%
confluence. Subsequent to removal of the medium, the cells
were washed once with 500 µl DMEM containing 2% FBS.
The fluorescent antibody anti‑human insulin‑like growth
factor‑1 receptor (IGF‑1R; eBioscience; cat. no. 16‑8849;
1:20) was added to the DMEM containing 2% FBS. The cells
were cultured in the new medium with antibody at 37˚C with
5% CO2 in a humidified incubator for 10 min. The medium

was discarded and the cells were washed once with DMEM
containing 2% FBS without antibody. Subsequently, DMEM
with 2% FBS was added into the dishes. The prepared dishes
were placed into the CO2 incubator of a laser scanning confocal
fluorescence microscope. IGF‑1R signal was recorded using
laser scanning confocal microscopy.
Cell immunostaining. U373‑MG cells were cultured in small
glass dishes as aforementioned. When cells reached 60‑75%
of the dishes, the medium was discarded and the cells were
washed once with 1 ml PBS. A volume of 1 ml fixation and
permeabilization solution (BD Biosciences) was added into
the dish, which was kept in the dark for 1 h at 4˚C. The fixing
reagent was discarded and the dish was washed once with 1 ml
PBS. Goat serum (5%; Jackson Immuno Research) in PBS
was used for blocking at room temperature for 1 h. The cells
were incubated with mouse monoclonal primary antibody
against ceramide (Enzo Life Sciences; cat. no. ALX‑804‑196;
1:10) at 4˚C overnight. Following three washes with PBS, the
cells were incubated with goat anti‑mouse IgG secondary
antibody (AF647‑conjugated; Jackson Immunologicals;
cat. no. 115‑606‑146; 1:300) for 1 h in the dark at room
temperature. The dish was washed three times with PBS and
visualized using laser scanning confocal microscopy.
For the regulation of IGF‑1R expression, U373‑MG cells
were divided into the DMSO and Desi groups. Cells from the
DMSO group represented the control group and were treated
with DMSO only and stimulated with insulin for 30 min.
Cells from the Desi group were treated with the drug Desi and
stimulated with insulin for 30 min.
Western blotting. The glioma cell line U373‑MG was lysed
with NP40 lysis buffer (Thermo Fisher Scientific, Inc.). The
protein density in each sample was determined by ultraviolet
spectrometry and adjusted to the same density using loading
buffer. Total protein (5 µg) was separated by SDS‑PAGE
(10% gel) and transferred onto PVDF membranes (EMD
Millipore). The membranes were blocked at 4˚C overnight
with blocking buffer (pH 7.6) containing 5% nonfat dried milk
and incubated with rabbit anti‑human monoclonal antibody,
which was purchased from Cell Signaling Technology, Inc.
Immunoreactive proteins were stained using a chemiluminescent detection system. Membranes were subsequently washed
with stripping solution for 1 h and treated as aforementioned,
with mouse β‑actin antibody (ProteinTech Group, Inc.) as an
internal control. The relative target protein expression levels
were normalized to those of β‑actin.
For the regulation of PI3K/Akt pathway, U373‑MG cells
were divided into the DMSO and Desi groups. Cells from the
DMSO group represented the control group and were treated
with DMSO only. Cells from the Desi group were treated with
the drug Desi. Both groups were then stimulated with insulin
for 15, 30 and 60 min. Western blot analysis of these samples
was performed to observe the PI3K/Akt pathway.
Statistical analysis. ClinProTools™ software (version 2.2;
Bruker Corporation) was used to perform the statistical analysis
of the peaks. Wilcoxon rank‑sum test was used to compare
data from TBT and GBT groups. Data are presented as the
means ± standard deviation. Each experiment was repeated
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Table I. Lipid peaks with higher expression in TBT samples compared with GBT samples.
Bio‑marker (m/z)

P‑value

Expression in TBT (mean ± SD)

Expression in GBT (mean ± SD)

798.57
722.55
848.64
799.56
800.56
769.58 (SM)
828.57
849.65
770.56
773.54
755.58 (SM)
753.60 (SM)
771.57 (SM)
783.79 (SM)
797.60 (SM)

<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6

198.68±67.29
122.60±42.17
26.64±9.18
90.11±32.72
64.7±23.62
94.32±34.4
14.17±4.68
13.13±4.42
56.06±20.65
50.43±18.96
14.11±5.83
70.94±31.10
27.07±10.97
99.88±38.85
17.00±6.60

14.34±11.75
9.37±5.57
3.44±2
7.11±5.92
5.92±4.26
9.06±5.37
3.32±2.06
2.93±2.09
7.46±4.99
5.18±3.47
6.11±3.92
10.69±7.62
6.23±2.62
42.26±21.45
10.27±3.59

GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.

Table II. Lipid peaks with higher expression in GBT samples compared TBT samples.
Bio‑marker (m/z)

P‑value

Expression in TBT (mean ± SD)

Expression in GBT (mean ± SD)

758.60
759.60 (SM)
786.64
808.60
616.17
617.07
618.17
614.16
678.47
703.43 (SM)
729.45 (SM)
731.48 (SM)
741.54 (SM)
757.57 (SM)
781.59 (SM)
811.62 (SM)

<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6
<1x10‑6

11.31±4.45
6.84±5.15
11.49±5
11.79±4.41
23.52±26.34
15.61±17.58
6.52±5.76
3.6±2.9
2.91±1.34
2.50±1.00
3.28±1.60
18.51±15.14
7.82±4.55
12.39±4.88
10.40±4.58
13.46±6.05

142.89±64.64
62.44±30.06
88.97±43.94
26.3±13.68
264.5±274.96
189.39±211.06
70.8±82.58
23.38±25.52
22.32±13.36
40.01±28.42
16.56±8.60
85.24±45.36
10.49±5.70
19.34±7.93
20.64±8.47
21.62±11.03

GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.

three times. P<0.01 was considered to indicate a statistically
significant difference.
Results
Screening of lipid biomarkers between GBT and TBT samples.
In the present study, three GBT samples and three TBT samples
were collected, sliced and analyzed by MALDI‑TOF‑MS. The
mass spectrum peaks were analyzed using FlexImaging software Ver3.0. Increased attention was paid to the differential

expression peaks of lipid biomarkers in GBT and TBT samples.
A total of 15 lipid peaks exhibited a higher expression intensity
in normal control TBT samples compared with GBT samples
(Table I). Another 16 lipid peaks exhibited a higher expression
intensity in GBT samples compared with normal control TBT
samples (Table II).
The expression intensity of the lipid peaks of 798.57,
722.55, 799.56, 769.58 and 783.79 m/z was markedly
increased in the TBT samples compared with the GBT
samples (Table I). Taking the peak of 798.57 m/z as an
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Figure 1. MALDI‑imaging results of sphingomyelin peaks in GBT and normal
control TBT samples. MALDI‑imaging results of 741.54, 759.60, 769.58 and
771.57 m/z are shown. GBT, glioma brain tissue; TBT, trauma brain tissue.

Figure 3. Movement of IGF‑1R. The distribution status of IGF‑1R on the cell
membrane was recorded by live staining technology. The movement track of
IGF‑1R can be observed with the laser scanning confocal microscopy at 0, 5,
10 and 20 min. IGF‑1R, insulin‑like growth factor‑1 receptor. Scale bar, 50 µm.

Figure 2. Distribution of ceramide and IGF‑1R on the cell membrane.
(A) Distribution of ceramide was obtained by immunostaining.
(B) Distribution of IGF‑1R was obtained by live staining. IGF‑1R, insulin‑like
growth factor‑1 receptor. Scale bar, 50 µm.

example, its expression intensity in normal control TBT
samples was as high as 198.68, while its expression in GBT
was decreased to 14.34.
Among these lipid peaks, the 758.60, 786.64, 617.07, 703.43
and 731.48 m/z peaks exhibited markedly higher expression
intensity in GBT samples compared with TBT samples. Taking
the peak of 758.60 m/z as an example, its expression value in
GBT was as high as 142.89, while its expression in normal
control TBT was decreased to 11.31. Some of the differentially
expressed lipid peaks in Tables I and II have the potential to
serve as clinical diagnosis biomarkers for the detection and
treatment of glioma.
Identification of lipid peaks. A total of 31 lipid peaks were
detected using MALDI‑TOF‑MS, and 14 of these lipid peaks
were identified as sphingomyelin (SM) using the second mass
spectrum. These 14 peaks are listed and marked in Tables I and II
with the label ‘SM’. The SM peak with the m/z value of 769.58
had an intensity of 94.32 in TBT and the SM peak with the
m/z value of 753.60 had an intensity of 70.94 in TBT (Table I).
Table III shows the structural data for nine SM peaks.

Figure 4. Expression of IGF‑1R on the cell surface. The immunostaining
results of two groups of glioma U373‑MG cells are shown. Cells in the two
groups were treated with insulin. The influence of drug Desi on IGF‑1R
expression was observed by comparing the two groups. Desi, desipramine;
IGF‑1R, insulin‑like growth factor‑1 receptor. Scale bar, 50 µm.

Verif ication of the expression of lipid peaks with
MALDI‑imaging. A total of 14 peaks were identified as SM.
Due to the important role of SM in cell signal transduction, verification of the expression of SM peaks with MALDI‑imaging
was performed. Fig. 1 shows the MALDI‑imaging results
of four SM peaks. The sample patterns on the left are the
MALDI‑imaging results from TBT samples and the sample
patterns on the right are the MALDI‑imaging results from
GBT samples. The expression intensities of the SM peaks with
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Figure 5. Expression levels of proteins associated with the PI3K/Akt pathway. Western blotting results of phosphorylated and total Src, S6k and Akt levels.
U373‑MG cells were treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated with DMSO while the other group was treated with Desi. P‑,
phosphorylated‑; S6k, ribosomal protein S6 kinase B1; Src, SRC proto‑oncogene non‑receptor tyrosine kinase; T‑, total‑; Desi, desipramine.

Table III. Structural data of various sphingomyelin peaks.
Biomarker (m/z)

Common name

Chemical composition

741.54
755.58
757.57
769.58
771.57
797.60
811.62
783.79
729.45

SM(d18:1/16:0)
SM(d18:1/17:0)
SM(d18:0/17:0)
SM(d18:1/18:0)
SM(d18:0/18:0)
SM(d18:1/20:0)
SM(d16:1/23:0)
SM(d18:1/19:0)
SM(d18:0/15:0)

[C39H79N2O6P+K] 1+
[C40H81N2O6P+K] 1+
[C40H83N2O6P+K] 1+
[C41H83N2O6P+K] 1+
[C41H85N2O6P+K] 1+
[C43H87N2O6P+K] 1+
[C44H89N2O6P+K] 1+
[C42H85N2O6P+K] 1+
[C38H79N2O6P+K] 1+

m/z values of 769.58, 771.57, 797.60, 783.79 and 753.60 were
higher in the normal control TBT samples compared with in
the GBT samples. The expression intensities of the SM peaks
with m/z values of 741.54, 781.59, 759.60, 757.57, 731.48 and
703.43 were higher in GBT samples compared with in normal
control TBT samples. The results of the MALDI‑imaging
experiments were consistent with the expression intensity
results from the MALDI‑TOF‑MS experiments.
Regulation and control of the expression properties of
insulin‑like growth factor‑1 receptor (IGF‑1R) and the
PI3K/AKT pathway. Firstly, SM biomarkers, which were
differentially expressed between GBT and TBT samples,
were identified. Subsequently, the regulation of IGF‑1R and
the PI3K/AKT pathway by ceramide were investigated. The
regulatory effect of ceramide on IGF‑1R and the PI3K/Akt
pathway was investigated using the glioma cell line U373‑MG.
Distribution of ceramide and IGF‑1R on the cell membrane.
The distribution characteristics of ceramide and IGF‑1R on
the cell membrane were observed by immunostaining. Fig. 2A
shows the distribution of ceramide, as revealed by immunostaining. It was identified that ceramide was made up of lipid
rafts, and large quantities of ceramide aggregated to form

Figure 6. Western blotting quantitative result for P‑Akt. U373‑MG cells were
treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated
with DMSO whereas the other group was treated with Desi. Desi, desipramine.

an areatus‑like distribution. Fig. 2B shows the live staining
pattern of IGF‑1R relative to ceramide. It was revealed that
IGF‑1R formed an areatus‑like distribution that was similar to
the distribution of ceramide.
Observation of the movement of IGF‑1R with live staining tech‑
nology. The movement of IGF‑1R, a ceramide receptor (19), on
the cell membrane was recorded with live staining technology.
Fig. 3 illustrates the movement of IGF‑1R, as visualized
with live cell staining technology. The cell dish was placed
into a CO2 incubator and observed via confocal microscopy
at 37˚C with 5% CO2. The recording times were 0, 5, 10 and
20 min. At 0 min, IGF‑1R fluorescence was observed on the
cell membrane, whereas IGF‑1R fluorescence in the inner area
of some cells was not clear. As the recording time increased,
the IGF‑1R fluorescence in the inner area of cells increased.
When the recording time reached 20 min, the inner area of
numerous cells presented high fluorescence intensity. IGF‑1R
fluorescence was indicated with arrows in Fig. 3.
Regulation of the expression of IGF‑1R. Data from Fig. 4
indicated that the expression level of phosphorylated IGF‑1R
was markedly stimulated by insulin when the glioma cell line
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U373‑MG was treated with DMSO as a control. Compared
with the fluorescence intensity at 0 min in the DMSO
group and the fluorescence intensity at 0 min in the Desi
group, the expression level of phosphorylated IGF‑1R was
significantly decreased when U373‑MG cells were treated
with Desi. In the DMSO group, the fluorescence intensity
of phosphorylated IGF‑1R was higher when the cells were
stimulated with insulin for 30 min. In the Desi group, the
fluorescence intensity of phosphorylated IGF‑1R was not
markedly increased when cells were further stimulated with
insulin for 30 min.
Regulation of the PI3K/Akt pathway. Results on the PI3K/Akt
pathway regulation are presented in Fig. 5. The expression
intensity of phosphorylated‑(P‑)Akt, P‑SRC proto‑oncogene
non‑receptor tyrosine kinase (Src) and P‑ribosomal protein S6
kinase B1 (S6k) in DMSO group increased gradually with
increasing time of treatment with insulin. Furthermore,
the influence of insulin in Desi group was weakened by the
application of Desi. Taking the P‑Akt as an example, its quantitative result is shown in Fig. 6. The relative intensity of P‑Akt
in group DMSO at 0 min is 0.70, while that in group Desi
decreases to 0.16. Furthermore, the relative intensity of P‑Akt
in group Desi are less than that in group DMSO at 15, 30 and
60 min.
Discussion
In the present study, MALDI‑imaging and MALDI‑TOF‑MS
were used to investigate the differences in the expression
levels of lipid biomarkers in GBT and TBT samples. A total
of 31 lipid peaks with differential expression properties were
detected in the GBT and TBT samples. A total of 15 lipid
peaks exhibited higher expression intensity in TBT compared
with GBT samples. Furthermore, 14 lipid peaks were
identified as sphingomyelin peaks. As previously reported,
sphingomyelin can be hydrolyzed into ceramide via acid
sphingomyelinase (ASM) (20,21).The results demonstrated
that ceramide and IGF‑1R had similar membrane distribution. The live cell staining results indicated that IGF‑1R
slowly entered the cell from the cell membrane, resulting
in increased IGF‑1R fluorescence in the inner area of cell.
These results were in accordance with a previous study that
reported that ceramide can bind to IGF‑1R and is involved
in cell signal transduction (22). The drug Desi was able to
inhibit the accumulation of ceramide on the cell membrane.
Insulin was able to stimulate IGF‑1R expression, although
IGF‑1R expression was inhibited by treatment with Desi.
Similar results were also observed for the expression levels of
proteins P‑Src, P‑Akt and P‑S6k from the PI3K/Akt signaling
pathway. Previous studies reported that the dysregulation of
the IGF‑1R signaling pathway results in the development of
malignant gliomas (19,23,24). In addition, glioma cell senescence and apoptosis can be influenced by the activity of the
PI3K/Akt signaling pathway (25,26).
Due to the difficulty of obtaining brain tissues, only three
GBT samples and three normal control TBT samples were
collected and used in the present study. For MALDI‑imaging,
it is advantageous to obtain cancer tissues and normal tissues
from the same individual; however, it is difficult to perform

experiments on glioma tissue and normal brain tissue from the
same person. Therefore, the brain tissues for glioma research
were usually collected from different individuals (27‑29). The
results of the present study were based on a limited sample
size, and the findings would be more valuable and reliable
if they were based on a larger sample size. These first‑stage
results may serve as the research foundation for further
studies. There are several topics requiring further investigation, including how the opposite alterations in the same type
of lipid biomarkers may be used to form a diagnostic pattern
for patients with glioma. Additionally, it should be investigated
how to predict the functional effect of these differentially
expressed lipid biomarkers between GBT and normal TBT by
pathway enrichment analysis. In the future, these issues will be
addressed in a study with a larger sample size.
In conclusion, the present study demonstrated that sphingomyelin peaks may be identified as biomarkers in GBT samples
compared with normal control TBT samples. Furthermore,
insulin could stimulate the high expression of ceramide and
of P‑Akt from the PI3K/Akt signaling pathway. However,
Desi inhibited the increase in ceramide and P‑Akt expression.
Future study will investigate the association between these
sphingomyelins and the survival rate of patients with glioma,
and the expression intensity variation of these sphingomyelin
along with the clinical treatment process of patients with
glioma.
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